Biotechnology stocks are high-risk, high-reward investments in companies developing novel therapeutics, gene therapies, and biologics. Our AI examines pipeline strength, clinical trial progress, cash runway, and partnership deals from SEC filings to identify the most promising biotech investments.
Top Biotechnology Stocks in 2026
Top-rated biotechnology stocks ranked by AI confidence score. Dual AI analysis (Claude + ChatGPT) based on SEC 10-K and 10-Q filings. Last Updated: June 2026
KRYS
Confidence
82%
NBIX
Confidence
81%
ELMD
Confidence
80%
AMGN
Confidence
79%
GILD
Confidence
78%
ADMA
Confidence
76%
MASI
Confidence
76%
EXEL
Confidence
75%
NAGE
Confidence
71%
TARS
Confidence
70%
RGEN
Confidence
70%
IMCR
Confidence
66%
All Biotechnology Stocks (203)
| Ticker | Company | AI Rating | Confidence | Action |
|---|---|---|---|---|
| AIM | AIM ImmunoTech Inc. | D | 96% | View Analysis → |
| ARMP | Armata Pharmaceuticals, Inc. | D | 96% | View Analysis → |
| NIMU | NON INVASIVE MONITORING SYSTEMS INC /FL/ | D | 96% | View Analysis → |
| IRME | IR-Med, Inc. | D | 96% | View Analysis → |
| ENDV | ENDONOVO THERAPEUTICS, INC. | D | 96% | View Analysis → |
| SNYR | Synergy CHC Corp. | D | 95% | View Analysis → |
| ZIVOW | Zivo Bioscience, Inc. | D | 95% | View Analysis → |
| YBGJ | Yubo International Biotech Ltd | D | 95% | View Analysis → |
| TVGNW | Tevogen Bio Holdings Inc. | D | 95% | View Analysis → |
| TCRG | Cannaisseur Group Inc. | D | 95% | View Analysis → |
| SCLXW | Scilex Holding Co | D | 95% | View Analysis → |
| POSC | POSITRON CORP | D | 95% | View Analysis → |
| PLSH | PANACEA LIFE SCIENCES HOLDINGS, INC. | D | 95% | View Analysis → |
| NTRR | NEUTRA CORP. | D | 94% | View Analysis → |
| BCDA | BioCardia, Inc. | D | 93% | View Analysis → |
| BCAB | BioAtla, Inc. | D | 93% | View Analysis → |
| FTII | FutureTech II Acquisition Corp. | D | 93% | View Analysis → |
| ESLAW | Estrella Immunopharma, Inc. | D | 93% | View Analysis → |
| ENZN | ENZON PHARMACEUTICALS, INC. | D | 93% | View Analysis → |
| ATRA | Atara Biotherapeutics, Inc. | D | 92% | View Analysis → |
| STEX | Streamex Corp. | D | 92% | View Analysis → |
| TARA | Protara Therapeutics, Inc. | D | 92% | View Analysis → |
| CVM | CEL SCI CORP | D | 92% | View Analysis → |
| PLUR | Pluri Inc. | D | 92% | View Analysis → |
| VANI | Vivani Medical, Inc. | D | 92% | View Analysis → |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | D | 92% | View Analysis → |
| ZEOX | Zeo ScientifiX, Inc. | D | 92% | View Analysis → |
| VACHW | Voyager Acquisition Corp./Cayman Islands | D | 92% | View Analysis → |
| GTHP | GUIDED THERAPEUTICS INC | D | 92% | View Analysis → |
| GPLB | Green Planet Bio Engineering Co. Ltd. | D | 92% | View Analysis → |
| OTLK | Outlook Therapeutics, Inc. | D | 90% | View Analysis → |
| CRIS | CURIS INC | C | 90% | View Analysis → |
| XFOR | X4 Pharmaceuticals, Inc | D | 90% | View Analysis → |
| PCVX | Vaxcyte, Inc. | D | 90% | View Analysis → |
| TIVC | Tivic Health Systems, Inc. | D | 90% | View Analysis → |
| RAPH | Raphael Pharmaceutical Inc. | D | 90% | View Analysis → |
| LIMNW | Liminatus Pharma, Inc. | D | 90% | View Analysis → |
| FNCH | Finch Therapeutics Group, Inc. | D | 90% | View Analysis → |
| PHGE | BiomX Inc. | D | 88% | View Analysis → |
| INKT | MiNK Therapeutics, Inc. | D | 88% | View Analysis → |
| CRDF | Cardiff Oncology, Inc. | D | 88% | View Analysis → |
| TIL | Instil Bio, Inc. | D | 88% | View Analysis → |
| ATYR | aTYR PHARMA INC | D | 88% | View Analysis → |
| PTHS | Pelthos Therapeutics Inc. | D | 88% | View Analysis → |
| MGTX | MeiraGTx Holdings plc | D | 88% | View Analysis → |
| SGMO | SANGAMO THERAPEUTICS, INC | D | 88% | View Analysis → |
| EXOZ | EXOZYMES INC. | D | 88% | View Analysis → |
| AGEN | AGENUS INC | D | 88% | View Analysis → |
| SLXNW | Silexion Therapeutics Corp | D | 88% | View Analysis → |
| RVMDW | Revolution Medicines, Inc. | D | 88% | View Analysis → |
| QTIWW | QT IMAGING HOLDINGS, INC. | D | 88% | View Analysis → |
| SLDB | Solid Biosciences Inc. | C | 87% | View Analysis → |
| NUWE | Nuwellis, Inc. | D | 87% | View Analysis → |
| POCI | PRECISION OPTICS CORPORATION, INC. | D | 87% | View Analysis → |
| DYAI | DYADIC INTERNATIONAL INC | C | 87% | View Analysis → |
| SRZNW | Surrozen, Inc./DE | D | 87% | View Analysis → |
| CRBU | Caribou Biosciences, Inc. | C | 86% | View Analysis → |
| RGNX | REGENXBIO Inc. | D | 86% | View Analysis → |
| IBRX | ImmunityBio, Inc. | D | 86% | View Analysis → |
| ECOR | electroCore, Inc. | C | 86% | View Analysis → |
| ESMC | ESCALON MEDICAL CORP | C | 86% | View Analysis → |
| STRO | SUTRO BIOPHARMA, INC. | D | 85% | View Analysis → |
| VOR | Vor Biopharma Inc. | D | 85% | View Analysis → |
| SNTI | Senti Biosciences, Inc. | D | 85% | View Analysis → |
| VYGR | Voyager Therapeutics, Inc. | D | 85% | View Analysis → |
| VIVS | VivoSim Labs, INC. | D | 85% | View Analysis → |
| TLRY | Tilray Brands, Inc. | D | 85% | View Analysis → |
| JUSHF | Jushi Holdings Inc. | D | 85% | View Analysis → |
| ALEC | Alector, Inc. | C | 84% | View Analysis → |
| NXL | Nexalin Technology, Inc. | D | 84% | View Analysis → |
| OCGN | Ocugen, Inc. | D | 84% | View Analysis → |
| IPHYF | Innate Pharma SA | C | 84% | View Analysis → |
| GHBWF | Glass House Brands Inc. | C | 84% | View Analysis → |
| ENGNW | enGene Holdings Inc. | C | 84% | View Analysis → |
| ELUT | ELUTIA INC. | C | 83% | View Analysis → |
| CV | CapsoVision, Inc | D | 83% | View Analysis → |
| MGX | Metagenomi Therapeutics, Inc. | C | 83% | View Analysis → |
| LXEO | Lexeo Therapeutics, Inc. | C | 83% | View Analysis → |
| BTMD | biote Corp. | C | 83% | View Analysis → |
| LEEEF | Leef Brands Inc. | D | 83% | View Analysis → |
| HUMAW | Humacyte, Inc. | D | 83% | View Analysis → |
| EVAX | Evaxion A/S | C | 83% | View Analysis → |
| FDMT | 4D Molecular Therapeutics, Inc. | C | 82% | View Analysis → |
| CMPX | Compass Therapeutics, Inc. | C | 82% | View Analysis → |
| CGEM | Cullinan Therapeutics, Inc. | C | 82% | View Analysis → |
| ARTV | Artiva Biotherapeutics, Inc. | C | 82% | View Analysis → |
| ALLO | Allogene Therapeutics, Inc. | D | 82% | View Analysis → |
| ENTX | Entera Bio Ltd. | C | 82% | View Analysis → |
| DTIL | PRECISION BIOSCIENCES INC | C | 82% | View Analysis → |
| KRYS | Krystal Biotech, Inc. | A | 82% | View Analysis → |
| JSPRW | Jasper Therapeutics, Inc. | D | 82% | View Analysis → |
| FATE | FATE THERAPEUTICS INC | C | 81% | View Analysis → |
| ALGS | Aligos Therapeutics, Inc. | C | 81% | View Analysis → |
| NBIX | NEUROCRINE BIOSCIENCES INC | A | 81% | View Analysis → |
| FTLF | FITLIFE BRANDS, INC. | C | 80% | View Analysis → |
| MTEX | MANNATECH INC | C | 80% | View Analysis → |
| ELMD | Electromed, Inc. | A | 80% | View Analysis → |
| ABOS | Acumen Pharmaceuticals, Inc. | C | 80% | View Analysis → |
| NVAX | NOVAVAX INC | C | 80% | View Analysis → |
| BCRX | BIOCRYST PHARMACEUTICALS INC | B | 80% | View Analysis → |
| NDRA | ENDRA Life Sciences Inc. | D | 79% | View Analysis → |
| IRIX | IRIDEX CORP | C | 79% | View Analysis → |
| INBX | Inhibrx Biosciences, Inc. | C | 79% | View Analysis → |
| AMGN | AMGEN INC | A | 79% | View Analysis → |
| FONR | FONAR CORP | B | 78% | View Analysis → |
| TECX | Tectonic Therapeutic, Inc. | C | 78% | View Analysis → |
| STXS | Stereotaxis, Inc. | C | 78% | View Analysis → |
| EDIT | Editas Medicine, Inc. | C | 78% | View Analysis → |
| LONA | LeonaBio, Inc. | C | 78% | View Analysis → |
| GILD | GILEAD SCIENCES, INC. | A | 78% | View Analysis → |
| SABSW | SAB Biotherapeutics, Inc. | D | 78% | View Analysis → |
| PMCB | PharmaCyte Biotech, Inc. | C | 78% | View Analysis → |
| HYEX | HEALTHY EXTRACTS INC. | C | 78% | View Analysis → |
| CABA | Cabaletta Bio, Inc. | C | 77% | View Analysis → |
| ACOG | Alpha Cognition Inc. | C | 77% | View Analysis → |
| CCCC | C4 Therapeutics, Inc. | C | 77% | View Analysis → |
| CGON | CG Oncology, Inc. | C | 76% | View Analysis → |
| CRON | Cronos Group Inc. | C | 76% | View Analysis → |
| CGTX | COGNITION THERAPEUTICS INC | C | 76% | View Analysis → |
| ADMA | ADMA BIOLOGICS, INC. | A | 76% | View Analysis → |
| MASI | MASIMO CORP | A | 76% | View Analysis → |
| MRNA | Moderna, Inc. | C | 76% | View Analysis → |
| ITGR | Integer Holdings Corp | C | 76% | View Analysis → |
| SANA | Sana Biotechnology, Inc. | C | 75% | View Analysis → |
| CADL | Candel Therapeutics, Inc. | C | 75% | View Analysis → |
| NRXS | Neuraxis, INC | C | 75% | View Analysis → |
| CHRS | Coherus Oncology, Inc. | C | 75% | View Analysis → |
| USNA | USANA HEALTH SCIENCES INC | C | 75% | View Analysis → |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | C | 75% | View Analysis → |
| TECH | BIO-TECHNE Corp | B | 75% | View Analysis → |
| EXEL | EXELIXIS, INC. | A | 75% | View Analysis → |
| AXGN | Axogen, Inc. | C | 75% | View Analysis → |
| MEHA | Functional Brands Inc. | C | 75% | View Analysis → |
| AURA | Aura Biosciences, Inc. | C | 74% | View Analysis → |
| AUTL | Autolus Therapeutics plc | C | 74% | View Analysis → |
| KOD | Kodiak Sciences Inc. | C | 74% | View Analysis → |
| KYTX | Kyverna Therapeutics, Inc. | C | 74% | View Analysis → |
| BDTX | Black Diamond Therapeutics, Inc. | C | 74% | View Analysis → |
| INMB | Inmune Bio, Inc. | C | 74% | View Analysis → |
| DNLI | Denali Therapeutics Inc. | C | 74% | View Analysis → |
| ADPT | Adaptive Biotechnologies Corp | B | 74% | View Analysis → |
| NAII | NATURAL ALTERNATIVES INTERNATIONAL INC | C | 74% | View Analysis → |
| REPL | Replimune Group, Inc. | D | 74% | View Analysis → |
| MRMD | MARIMED INC. | C | 74% | View Analysis → |
| BEAM | Beam Therapeutics Inc. | B | 73% | View Analysis → |
| KYMR | Kymera Therapeutics, Inc. | C | 73% | View Analysis → |
| PRME | Prime Medicine, Inc. | C | 72% | View Analysis → |
| IMA | ImageneBio, Inc. | C | 72% | View Analysis → |
| PROK | PROKIDNEY CORP. | C | 72% | View Analysis → |
| FENC | FENNEC PHARMACEUTICALS INC. | C | 72% | View Analysis → |
| QNCX | Quince Therapeutics, Inc. | C | 72% | View Analysis → |
| NMRA | Neumora Therapeutics, Inc. | C | 72% | View Analysis → |
| LENZ | LENZ Therapeutics, Inc. | C | 72% | View Analysis → |
| TNYA | Tenaya Therapeutics, Inc. | C | 72% | View Analysis → |
| CRSP | CRISPR Therapeutics AG | C | 72% | View Analysis → |
| TWST | Twist Bioscience Corp | B | 72% | View Analysis → |
| RXRX | RECURSION PHARMACEUTICALS, INC. | C | 72% | View Analysis → |
| RLAY | Relay Therapeutics, Inc. | C | 72% | View Analysis → |
| BIIB | BIOGEN INC. | B | 72% | View Analysis → |
| VASO | VASO Corp | B | 72% | View Analysis → |
| GLUC | Glucose Health, Inc. | D | 72% | View Analysis → |
| IVVD | Invivyd, Inc. | C | 71% | View Analysis → |
| HYPR | Hyperfine, Inc. | C | 71% | View Analysis → |
| CBLL | Ceribell, Inc. | B | 71% | View Analysis → |
| APGE | Apogee Therapeutics, Inc. | C | 71% | View Analysis → |
| NAGE | Niagen Bioscience, Inc. | A | 71% | View Analysis → |
| IMVT | Immunovant, Inc. | C | 70% | View Analysis → |
| GLUE | Monte Rosa Therapeutics, Inc. | C | 70% | View Analysis → |
| MAZE | Maze Therapeutics, Inc. | B | 70% | View Analysis → |
| PASG | Passage BIO, Inc. | C | 70% | View Analysis → |
| VCEL | Vericel Corp | B | 70% | View Analysis → |
| TARS | Tarsus Pharmaceuticals, Inc. | A | 70% | View Analysis → |
| RGEN | REPLIGEN CORP | A | 70% | View Analysis → |
| KLRS | Kalaris Therapeutics, Inc. | C | 69% | View Analysis → |
| LIVN | LivaNova PLC | B | 69% | View Analysis → |
| INTS | INTENSITY THERAPEUTICS, INC. | C | 68% | View Analysis → |
| SRRK | Scholar Rock Holding Corp | C | 68% | View Analysis → |
| BLFS | BIOLIFE SOLUTIONS INC | B | 68% | View Analysis → |
| TMDX | TransMedics Group, Inc. | B | 68% | View Analysis → |
| IKT | Inhibikase Therapeutics, Inc. | C | 67% | View Analysis → |
| LCTX | Lineage Cell Therapeutics, Inc. | C | 66% | View Analysis → |
| DFTX | Definium Therapeutics, Inc. | C | 66% | View Analysis → |
| INAB | IN8BIO, INC. | C | 66% | View Analysis → |
| IMCR | Immunocore Holdings plc | A | 66% | View Analysis → |
| ZURA | Zura Bio Ltd | B | 65% | View Analysis → |
| VIR | Vir Biotechnology, Inc. | C | 65% | View Analysis → |
| TSHA | Taysha Gene Therapies, Inc. | B | 65% | View Analysis → |
| HALO | HALOZYME THERAPEUTICS, INC. | B | 64% | View Analysis → |
| HCIL | Hongchang International Co., Ltd | C | 64% | View Analysis → |
| TCNNF | Trulieve Cannabis Corp. | B | 62% | View Analysis → |
| IPSC | Century Therapeutics, Inc. | C | 58% | View Analysis → |
| OM | Outset Medical, Inc. | C | 58% | View Analysis → |
| PALI | PALISADE BIO, INC. | B | 55% | View Analysis → |
| PLX | Protalix BioTherapeutics, Inc. | B | 52% | View Analysis → |
| TCRX | TScan Therapeutics, Inc. | C | 50% | View Analysis → |
| VXRT | Vaxart, Inc. | B | 48% | View Analysis → |
| INMD | InMode Ltd. | B | 42% | View Analysis → |
| EIKN | Eikon Therapeutics, Inc. | B | 41% | View Analysis → |
| EDAP | EDAP TMS SA | B | 39% | View Analysis → |
| RGC | Regencell Bioscience Holdings Ltd | C | 22% | View Analysis → |
| MOLN | MOLECULAR PARTNERS AG | B | 18% | View Analysis → |
| MDWD | MediWound Ltd. | C | 15% | View Analysis → |
| MEOBF | MESOBLAST LTD | B | 5% | View Analysis → |
Frequently Asked Questions: Biotechnology Stocks
What are the best biotechnology stocks to buy in 2026?
Based on our dual AI fundamental analysis (Claude and ChatGPT), 12 biotechnology stocks have A+ or A grades in 2026. These are ranked by confidence score based on SEC 10-K and 10-Q filing analysis.
Which biotechnology stocks have A+ grades?
Currently, 0 biotechnology stocks have an A+ grade from our AI analysis. A+ indicates both Claude and ChatGPT agree on exceptional fundamentals with high confidence scores above 80%.
How does AI analyze biotechnology stocks?
Our dual AI system analyzes SEC EDGAR filings including revenue growth, profit margins, ROE, ROA, debt levels, and cash flow. Both Claude (Anthropic) and ChatGPT (OpenAI) independently evaluate each stock, then we combine their ratings for higher accuracy.
What is the AI confidence score?
AI confidence scores range from 0-100% and indicate how strongly the AI models agree on their rating. Higher confidence means clearer signals from SEC filing data. Biotechnology stocks with 80%+ confidence have the most reliable ratings.
Should I invest in biotechnology stocks in 2026?
Our AI analysis shows 12 Buy ratings vs 165 Sell ratings in the biotechnology sector. Individual stock fundamentals vary significantly - review each stock's detailed analysis. This is not investment advice.
How often are biotechnology stock ratings updated?
AI ratings are updated whenever companies file new SEC reports (10-K annually, 10-Q quarterly). Most biotechnology stocks are re-analyzed within 24-48 hours of new filings being published on SEC EDGAR.
What data sources are used for biotechnology stock analysis?
All analysis is based on official SEC EDGAR filings including Form 10-K (annual reports), Form 10-Q (quarterly reports), and other regulatory disclosures. We do not use price data or market sentiment - only fundamental financial data.
Compare Top Biotechnology Stocks
Part of: 💊 Healthcare Sector